Palvella Therapeutics, Inc. Increase (Decrease) in Prepaid Expense
Palvella Therapeutics, Inc. (PVLA) reported Increase (Decrease) in Prepaid Expense of $628.72 thousand for the 6-month period ending 2015-06-30, per its 10-Q filed 2015-08-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2015-08-13
- Palvella Therapeutics, Inc. increase (decrease) in prepaid expense for the quarter ending 2015-06-30 was $220.50K, a 749.96% increase year-over-year.
- Palvella Therapeutics, Inc. increase (decrease) in prepaid expense for the quarter ending 2015-03-31 was $408.22K, a 775.50% increase year-over-year.
- Palvella Therapeutics, Inc. increase (decrease) in prepaid expense for the quarter ending 2014-06-30 was $25.94K.
- Palvella Therapeutics, Inc. increase (decrease) in prepaid expense for the quarter ending 2014-03-31 was $46.63K.
- Palvella Therapeutics, Inc. increase (decrease) in prepaid expense for fiscal 2014 was $58.24K.
- Palvella Therapeutics, Inc. increase (decrease) in prepaid expense for fiscal 2013 was -$1.05K.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|
| 2015-06-30 | $220.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $628.72K 10-Q · filed 2015-08-13 | |
| 2015-03-31 | $408.22K 10-Q · filed 2015-05-14 | ||
| 2014-12-31 | $58.24K 10-K · filed 2015-03-30 | ||
| 2014-06-30 | $25.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $72.57K 10-Q · filed 2015-08-13 | |
| 2014-03-31 | $46.63K 10-Q · filed 2015-05-14 | ||
| 2013-12-31 | -$1.05K 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |